Key Players
Competitive Landscape
Key Players
Pfizer, Merck, GSK, Sanofi, Moderna, CSL Seqirus, Bavarian Nordic, Novavax, Serum Institute of India, Bharat Biotech, SINOVAC, SK bioscience and Zoetis are covered in the competitive discussion.
Pfizer, Merck, GSK and Sanofi compete on franchise products with their own approval histories in each country [4][6][7][8]. Moderna and Novavax compete on platform, with Novavax now relying on Sanofi for commercial reach [28][31]. CSL Seqirus and Bavarian Nordic serve seasonal and government preparedness demand [29][27]. Serum Institute of India, Bharat Biotech, SINOVAC and SK bioscience win pooled tenders and technology transfer deals on price and prequalification [25][24][32][33]. Zoetis supplies the animal segment [12]. These positions separate franchise value, platform risk and volume supply.
Table 7: Company Developments and Commercial Implications
| Evidence | Commercial effect | Buyer action |
|---|---|---|
| Moderna signs EU joint procurement contract for up to 24.0 million RSV doses, July 2026 [5][28] | Six countries hold supply options for four years without a purchase commitment | National programmes should decide eligibility early so that call-offs match the vaccination window |
| Bavarian Nordic agrees chikungunya vaccine technology transfer to Serum Institute of India, March 2026 [26] | A second manufacturing base can lower cost for endemic countries once prequalified | Procurement agencies should track WHO prequalification timing before planning introductions |
| SK bioscience agrees technology transfer with Colombia's VECOL, May 2026 [33] | Local production of varicella vaccine is planned under a ten-year investment programme | Regional buyers should compare local supply terms with existing import contracts |
How are the companies positioned?
Franchise owners sell high-value courses to funded adult and adolescent cohorts. Merck's GARDASIL and Pfizer's Prevnar family each exceeded USD 1.5 billion in their September 2026 quarters [6][4]. Volume manufacturers supply pooled procurement at low prices, as Serum Institute of India does for oral polio vaccine at 14.1 US cents per dose [16]. Platform companies depend on partners, with Sanofi leading Nuvaxovid commercial activity for Novavax [31].
What matters when a buyer qualifies a vaccine supplier?
Buyers check marketing authorisation, WHO prequalification where UN procurement applies, presentation and delivery timing. Serum Institute of India's CERVAVAC entered UN agency procurement only after prequalification in October 2026 [25]. Japan's ministry restricts routine older-adult pneumococcal vaccination to PCV20 [9]. Price per completed course counts more than price per vial, as the four-dose malaria schedule shows [22].
Which capabilities distinguish the vaccine offers?
Serotype coverage, adjuvant technology and manufacturing scale separate suppliers. GSK grew meningitis vaccine sales 21.0% in the three months to June 2026 [7]. CSL Seqirus sells adjuvanted and cell-based influenza vaccines that grew while the wider market softened [29]. Serum Institute of India cites annual capacity of 4.0 billion doses across its Pune sites [25]. Each capability changes which tenders a company can win.
How does geographic reach affect competition?
Reach decides which programmes a supplier can serve and at what price. SINOVAC drew 45.2% of first-half 2026 sales from overseas markets [32]. SK bioscience is entering Latin America through a technology transfer to Colombia [33]. Bavarian Nordic gained Canadian approval for its chikungunya vaccine in June 2026 after earlier US and EU approvals [27]. Companies with local release testing and registration teams in many countries can respond to schedule changes faster than importers.
Representative Company Overview
Table 8: Vaccines Market Representative Company Overview
| Company | Positioning | Verified activity |
|---|---|---|
| Pfizer Inc. | Pneumococcal conjugate and RSV franchise owner | Prevnar family revenue of USD 1,564.0 million and Abrysvo revenue of USD 303.0 million in third-quarter 2026 [4] |
| Merck & Co., Inc. | HPV, pneumococcal and live attenuated vaccine supplier | GARDASIL revenue of USD 1,995.0 million in third-quarter 2026, up 14.0% [6] |
| GSK plc | Shingles, meningitis and RSV vaccine portfolio | Vaccine sales grew 8.0% to GBP 2.3 billion in second-quarter 2026 [7] |
| Moderna, Inc. | mRNA respiratory vaccine developer | EU joint procurement contract for up to 24.0 million mRESVIA doses signed in July 2026 [28] |
| Serum Institute of India Pvt. Ltd. | High-volume supplier to pooled procurement | WHO prequalification of CERVAVAC in October 2026 and chikungunya vaccine manufacturing agreement with Bavarian Nordic in March 2026 [25][26] |
Research Methodology
FMI builds an annual revenue assessment from the cited coverage statistics, procurement records, national schedules and manufacturer results. The scope counts revenue from vaccine products for human and animal use and excludes administration supplies and antibodies. Segment comparisons use the same revenue base and mutually exclusive categories within each classification. Country forecasts combine funded eligibility, product specification and procurement rules with the global 2036 outlook. Validation checks units, dates, compound growth, segment totals and company roles. Secondary observations keep their original period and measurement basis [1][2][13][4].
